Maintenance Immunotherapy in MOGAD: Early Steroid Benefit, Dose Thresholds, and Disability Risk - Part 1
In part one of this series, Dr. Justin Abbatemarco and Dr. Benjamin P. Trewin discuss the major findings from his work. Read more about this abstract on the AAN website .
Read the full articleYou might also wanna read
Study of Combined GARP:TGF-β1/PD-1 Blockade as a Shock-and-kill Strategy in HIV-1 Cure
Conditions : HIV -1 Infection Interventions : Other: blood drawn Sponsors : Cliniques universitaires Saint-Luc- Université Catholique de Lou
clinicaltrials.gov·7d ago
Testosterone Replacement Therapy After the TRAVERSE Trial
Neutral safety finding for topical gel--green light for broader therapy?
Courageous Discourse·4d ago
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
Conditions : Hidradenitis Suppurativa Sponsors : Novartis Pharmaceuticals Not yet recruiting
clinicaltrials.gov·8d ago
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
Conditions : ALS (Amyotrophic Lateral Sclerosis); ALS - Amyotrophic Lateral Sclerosis; ALS Interventions : Drug: Foralumab Nasal; Drug: Plac
clinicaltrials.gov·9d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.